Search alternatives:
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mg » 5 mm (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mg » 5 mm (Expand Search)
-
40021
Presentation_1_Molecular Characterization and Expression of Cytochrome P450 Aromatase in Atlantic Croaker Brain: Regulation by Antioxidant Status and Nitric Oxide Synthase During H...
Published 2021“…Hypothalamic AROM activity and mRNA levels were also decreased by pharmacological treatment with N-ethylmaleimide (NEM, an alkylating drug that modifies sulfhydryl groups) of fish exposed to normoxic (DO: ∼6.5 mg/L) conditions. …”
-
40022
Data Sheet 7_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo...
Published 2024“…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
-
40023
Data Sheet 8_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo...
Published 2024“…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
-
40024
Data Sheet 4_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo...
Published 2024“…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
-
40025
Data Sheet 9_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo...
Published 2024“…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
-
40026
Data Sheet 6_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo...
Published 2024“…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
-
40027
Image 1_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo.jpeg...
Published 2024“…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
-
40028
Data Sheet 2_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo...
Published 2024“…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
-
40029
Data Sheet 1_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo...
Published 2024“…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
-
40030
Data Sheet 3_The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo...
Published 2024“…</p>Results<p>The results show that compound 16C has low toxicity (LD<sub>50</sub> > 5,000 mg/kg). Its pharmacokinetic profile is characterized by a short time to maximum concentration (Tmax = 0.24 h), high bioavailability (F = 71.29%), and short elimination half-life (T<sub>1/2kel</sub>) (intramuscular and intravenous administration was 2.20 and 1.89 h, respectively). …”
-
40031
Cordycepin prevents the esophageal stricture formation in the alkali-burn rat model by exerting anti-inflammatory and antifibrotic effects
Published 2021“…Methods Caustic esophageal burn was introduced by 37.5% of NaOH to distal esophagus. Thirty-two Wistar albino rats were divided in four groups: sham rats undergone laparotomy, treated with 0.9% NaCl; control rats injured with NaOH without cordycepin treatment; cordycepin group injured with NaOH, treated with 20 mg/kg cordycepin; prednisolone group injured with NaOH, treated with 1 mg/kg prednisolone for 28 days. …”
-
40032
Image 1_Regulation effect of seed priming on sowing rate of direct seeding of rice under salt stress.pdf
Published 2025“…<p>Direct seeding of rice (DSR) is a widely used method for its labor- and cost-saving advantages. …”
-
40033
Table 1_Regulation effect of seed priming on sowing rate of direct seeding of rice under salt stress.pdf
Published 2025“…<p>Direct seeding of rice (DSR) is a widely used method for its labor- and cost-saving advantages. …”
-
40034
FIGURE 6 from Targeting <i>MALAT1</i> Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer
Published 2023“…The experiments were performed with <i>n</i> = 3 biologically independent samples; the data represents mean ± SEM. Extra sums of the square F-test was used to compute the statistical significance and compare the curves in A. …”
-
40035
CaMKII regulates the number of DCVs entering the axon but not their trafficking properties.
Published 2020“…<p>(A) Schematic representation of AIS targeting; Na<sub>v</sub>II-III BFP was used to visualize the region of the AIS. …”
-
40036
Table_1_The effects of blurred visual inputs with different levels on the cerebral activity during free level walking.docx
Published 2023“…The cautious gait pattern, characterized by a decrease in gait speed (p < 0.001), a greater amplitude of deviation from the right ahead (p < 0.001), a prolonged stance time (p = 0.001), a restricted range of motion in the hip on the right side (p ≤ 0.010), and an increased knee flexion during stance on the left side (p = 0.014), was only detected at the status of V0. …”
-
40037
-
40038
-
40039
-
40040